Marker Therapeut Stock Price, News & Analysis

Marker Therapeutics (Nasdaq: MRKR) will present Phase 1 APOLLO data for MT-601 at the 67th ASH Annual Meeting, Dec 6-9, 2025 in Orlando.

Key results: in relapsed Non-Hodgkin lymphoma (NHL) patients ORR was 66% (8/12) with 50% CR; responses lasted 3–24 months with five patients ≥6 months and three >12 months. In Hodgkin lymphoma (HL) ORR was 78% (7/9) with 11% CR. No dose limiting toxicities or ICANS were reported; two participants had Grade 1 CRS. Company advanced to dose expansion at 400x10^6 cells in DLBCL post-CAR-T or CAR-T ineligible patients.

Marker Therapeutics (Nasdaq: MRKR) — Oct 6, 2025 announced the first patient was treated in the Phase 1 RAPID study testing MT-401, a multi-antigen recognizing (MAR) T cell off-the-shelf (OTS) product.

The first participant received the initial dose of 100x10^6 cells and was monitored for 28 days; the therapy was reported as well tolerated with no treatment-related adverse events. The OTS program initially targets AML and MDS and may expand to other indications. Marker said commercially sourced leukapheresis from healthy donors could enable treatment as fast as 72 hours. The program is supported by non-dilutive funding from the FDA, NIH SBIR, and CPRIT.

Marker Therapeutics (NASDAQ:MRKR), a clinical-stage immuno-oncology company, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York.

CEO Dr. Juan Vera will lead a fireside chat on September 10, 2025, from 12:30 to 1:00 p.m. EDT at the Lotte New York Palace Hotel. The management team will also conduct one-on-one meetings with investors to discuss their MAR T cell platform and clinical developments, including updates from the Phase 1 APOLLO study.

Investors can access the webcast through Marker's Investor Relations website under "Events and Presentations".

Marker Therapeutics (NASDAQ:MRKR) has reported encouraging results from its Phase 1 APOLLO study investigating MT-601, a Multi-Antigen Recognizing T cell product, for treating relapsed lymphoma. The study demonstrated a 66% objective response rate in Non-Hodgkin Lymphoma (NHL) patients, with 50% achieving complete response.

The trial included 24 B-cell lymphoma patients across 7 U.S. clinical sites, with doses ranging from 100x106–400x106 cells. Notable outcomes include 78% objective response rate in Hodgkin Lymphoma patients and durable responses lasting 3-24 months. The treatment showed a favorable safety profile with no dose-limiting toxicities or serious adverse events.

The company is advancing to the dose expansion phase, investigating MT-601 at the maximum dose of 400x106 cells in DLBCL patients who have relapsed after or are ineligible for CAR-T therapy.

Marker Therapeutics (Nasdaq: MRKR), a clinical-stage immuno-oncology company, announced its participation in the Canaccord Genuity 45th Annual Growth Conference. CEO Dr. Juan Vera will engage in a fireside chat on August 12, 2025, from 12:30 to 12:55 p.m. EDT at the InterContinental Boston Hotel.

During the conference, management will conduct one-on-one meetings with investors to discuss their Multi-Antigen Recognizing (MAR) T cell platform and clinical developments. Investors can access the webcast through Marker's IR website under "Events and Presentations".

Marker Therapeutics (MRKR) has partnered with Cellipont Bioservices for cGMP manufacturing of MT-601, their lead Multi-Antigen Recognizing T cell therapy. MT-601 is being tested in the Phase 1 APOLLO study for lymphoma patients who relapsed after anti-CD19 CAR-T therapy or are ineligible for it. Early results showed promising outcomes with a 78% objective response rate (7/9 patients) and 44.4% complete response rate (4 patients) within 4 weeks of treatment. Cellipont will provide technology transfer and manufacturing services from their 76,000-square-foot facility in The Woodlands, Texas. The collaboration aims to support clinical supply, potential pivotal trials, and commercial readiness for MT-601, particularly focusing on patients with diffuse large B-cell lymphoma (DLBCL).

Marker Therapeutics (NASDAQ: MRKR) reported positive developments in its Phase 1 APOLLO study evaluating MT-601, a MAR-T cell therapy for lymphoma patients. Key findings show that lymphodepletion improves MAR-T cells expansion and persistence. The study demonstrated: - 78% objective response rate (7 out of 9 patients) - 44.4% complete response rate (4 patients) within 4 weeks - No dose limiting toxicities or neurotoxicity syndrome - Significantly higher expansion and persistence of MT-601 MAR-T cell clones in patients receiving lymphodepletion The company reported its highest enrollment rate in early 2025, enrolling more patients in five months than in all of 2024. Clinical data readout from the APOLLO study is expected in summer 2025.

Marker Therapeutics (NASDAQ: MRKR) has announced its participation in a high-profile virtual panel discussion titled "Seven Years After FDA Approval – Have CD19 CAR-T Cells Met Expectations?" scheduled for May 28, 2025. CEO Dr. Juan Vera will present the company's MAR-T cell therapy platform, a novel non-engineered multi-antigen approach designed to address CAR-T therapy limitations. The one-hour webcast, produced by Demy-Colton and WBB Research Institute, will feature distinguished panelists including experts from Baylor College of Medicine, University of Colorado, and City of Hope. The event will explore the cell therapy landscape, current limitations of CAR-T therapies, and potential solutions through Marker's innovative approach.

Marker Therapeutics (Nasdaq: MRKR), a clinical-stage immuno-oncology company, has announced its participation in Canaccord Genuity's Horizons in Oncology Virtual Conference. CEO Dr. Juan Vera will join a panel discussion titled 'CAR-T in Solid Tumors and New T-cell Approaches – Breakthroughs Ahead?' scheduled for April 7, 2025, from 11:00 AM to 11:50 AM ET.

The company specializes in developing next-generation T cell-based immunotherapies for treating hematological malignancies and solid tumors. Their innovative platform features multi antigen recognizing (MAR)-T cell therapy, designed to simultaneously target multiple tumor-associated antigens. This approach has demonstrated promising clinical results in both hematologic malignancies and solid tumors.